Sales & Marketing News | pharmaphorum

News

Tenpoint eyes presbyopia drug launch after FDA nod

Tenpoint is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis, and LENZ with a dual-acting rival.

News

Digital musculoskeletal care firm Sword buys rival Kaia

US digital physical therapy specialist Sword Health has bought its competitor Kaia Health for $285 million, positioning it for expansion in Europe.

News

ADHD in wooden letters surrounded by white pills

Otsuka preps for July decision on centanafadine for ADHD

The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.

News

Halozyme diversifies in drug delivery with Surf Bio buy

Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.

News

Eikon prices its IPO, seeking to raise $318m

Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

Tenpoint eyes presbyopia drug launch after FDA nod

Digital musculoskeletal care firm Sword buys rival Kaia

Otsuka preps for July decision on centanafadine for ADHD

Halozyme diversifies in drug delivery with Surf Bio buy

Eikon prices its IPO, seeking to raise $318m

CMS's Medicare price negotiations start round three

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks